{
    "clinical_study": {
        "@rank": "161484", 
        "arm_group": [
            {
                "arm_group_label": "ASP2151", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP2151 placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex."
        }, 
        "brief_title": "Phase III Study of ASP2151 in Herpes Simplex Patients", 
        "condition": "Herpes Simplex", 
        "condition_browse": {
            "mesh_term": "Herpes Simplex"
        }, 
        "detailed_description": {
            "textblock": "A double-blind, randomized, placebo-controlled, parallel-group study will be conducted to\n      evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (labial/facial\n      herpes or recurrent genital herpes). The efficacy will be evaluated for the primary endpoint\n      defined as, \"the proportion of subjects achieving lesion healing by Day 8 of study\n      treatment\" to demonstrate the superiority of ASP2151 to placebo. The safety will be\n      evaluated based on adverse events, laboratory tests, vital signs, and ECGs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with a rash associated with moderate or severe herpes simplex, for which\n             oral antiviral medication is indicated\n\n               -  Labial/facial herpes: Patients with at least 10 papulae or vesicles/pustules\n\n               -  Recurrent genital herpes: Patients with at least 5 papulae or vesicles/pustules\n                  on the genital organs or in the genital and circumanal region\n\n          2. Patients who can start receiving the study drug within 48 hours after onset of rash\n\n          3. Age: 20 years or older, but younger than 80 years\n\n        Exclusion Criteria:\n\n          1. Patients who are not expected to have an adequate response to oral antiviral\n             medication\n\n          2. An extreme decline in immune function\n\n          3. Presence of serious complications\n\n          4. Patients found to meet any of the following conditions based on laboratory tests\n             performed within 14 days before informed consent:\n\n               -  AST or ALT \u2265 2.5 x upper limit of normal\n\n               -  Platelet count < lower limit of normal\n\n               -  Serum creatinine \u2265 1.5 mg/dL\n\n               -  Creatinine clearance < 30 mL/min\n\n          5. Current or previous history of malignant tumor within 5 years before informed consent\n\n          6. Diagnosis of autoimmune disease\n\n          7. Evidence of bone marrow suppression"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "453", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959295", 
            "org_study_id": "M522101-J11"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP2151", 
                "description": "200 mg once daily", 
                "intervention_name": "ASP2151", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP2151 placebo", 
                "description": "once daily", 
                "intervention_name": "ASP2151 placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nakano-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of ASP2151 in Herpes Simplex Patients \u2015 A Double-blind, Placebo-controlled Study \u2015", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects achieving lesion healing by Day 8 of study treatment", 
            "safety_issue": "No", 
            "time_frame": "8days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to healing", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to complete crusting", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to virus disappearance", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }
        ], 
        "source": "Maruho Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maruho Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}